Ionis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is a ribonucleic acid-targeted (RNA-targeted) drug discovery and development company. The Company is focused on discovering and developing antisense drugs. Its antisense drugs are used to treat a range of diseases, including cardiovascular; metabolic; severe and rare diseases, including neurological disorders, and cancer. Volanesorsen is a drug indicated to treat patients with high triglyceride levels, including patients with a genetic condition called familial chylomicronemia syndrome (FCS) and patients with partial lipodystrophy. It is focused on bringing its late-stage Phase III drugs, nusinersen, volanesorsen and IONIS-TTR to the market. Its lipid-lowering product, KYNAMRO (mipomersen sodium) injection, is on the market in the United States for patients with homozygous familial hypercholesterolemia (HoFH). Its products also include Alicaforsen, IONIS-DMPK-2.5, Plazomicin and IONIS-GCGR.